加载中
NASDAQHealthcareBiotechnology
最新数据
US$30.15
−US$0.50 · -1.63%
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
收盘时
US$30.15
−US$0.50 · -1.63%
盘后
US$30.20
+US$0.05 · +0.17%
10月12日 19:57 ET
盘中时间采用ET。市场数据可能有所延迟。
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
日内区间
当前US$30.15
52周区间
当前US$30.15
盘中时间采用ET。市场数据可能有所延迟。
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
日内区间
当前US$30.15
52周区间
当前US$30.15
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|
| 销货成本 | — | — | — | 1.5万 USD |
| 毛利 | — | — | — | −1.5万 USD |
| 研究与开发 | 9478.9万 USD | 6093.5万 USD | 2799.9万 USD | 911.5万 USD |
| 销售、一般及管理费用 | 3031万 USD | 2212万 USD | 818万 USD | 136.58万 USD |
| 营业费用 | 1.25亿 USD | 8305.5万 USD | 3617.9万 USD | 1035.2万 USD |
| 利息收入 | 1361.6万 USD | 1213.8万 USD | 252.7万 USD | — |
| 利息支出 | — | — | — | 28.5万 USD |
| 折旧和摊销 | 101.7万 USD | 83.9万 USD | 11.2万 USD | 1.5万 USD |
| 营业利润 | −1.25亿 USD | −8305.5万 USD | −3617.9万 USD | −1036.7万 USD |
| 净利润 | −1.11亿 USD | −7830.7万 USD | −3478.6万 USD | −1065.2万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI4802.41万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM2453.68万0.03%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF1619.79万0.02%954亿 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO857.17万0.05%180亿 USD0.06%US$112.27-0.35%
iShares Russell 2000 Growth ETFIWO811.53万0.06%139.17亿 USD0.24%US$353.71-0.86%
iShares Biotechnology ETFIBB683.69万0.06%108.2亿 USD0.44%US$204.26-1.08%
Dimensional - US Small Cap ETFDFAS618.36万0.02%338.69亿 USD0.31%US$78.17-0.23%
State Street SPDR S&P Pharmaceuticals ETFXPH598.86万1.30%4.62亿 USD0.35%US$64.01-0.99%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASState Street SPDR S&P Pharmaceuticals ETFXPHAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
